Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) CFO Sean F. Moran purchased 1,500 shares of Corbus Pharmaceuticals Holdings stock in a transaction that occurred on Friday, November 10th. The shares were purchased at an average price of $7.04 per share, for a total transaction of $10,560.00. Following the transaction, the chief financial officer now directly owns 340,910 shares in the company, valued at approximately $2,400,006.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) traded up $0.45 during midday trading on Thursday, hitting $7.05. 778,632 shares of the company traded hands, compared to its average volume of 811,980. Corbus Pharmaceuticals Holdings, Inc. has a twelve month low of $5.30 and a twelve month high of $10.50.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.02. The business had revenue of $0.80 million for the quarter. Corbus Pharmaceuticals Holdings had a negative net margin of 1,040.41% and a negative return on equity of 96.02%. analysts forecast that Corbus Pharmaceuticals Holdings, Inc. will post -0.61 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was first published by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/11/16/corbus-pharmaceuticals-holdings-inc-crbp-cfo-purchases-10560-00-in-stock.html.

Several research firms recently issued reports on CRBP. Noble Financial increased their price target on shares of Corbus Pharmaceuticals Holdings from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. Cantor Fitzgerald reiterated a “buy” rating and set a $24.00 price target on shares of Corbus Pharmaceuticals Holdings in a research report on Wednesday, September 20th. ValuEngine lowered shares of Corbus Pharmaceuticals Holdings from a “hold” rating to a “sell” rating in a research report on Wednesday, September 13th. Finally, BidaskClub upgraded shares of Corbus Pharmaceuticals Holdings from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $20.75.

A number of large investors have recently modified their holdings of the stock. Yellowstone Partners LLC bought a new position in Corbus Pharmaceuticals Holdings in the 3rd quarter valued at approximately $110,000. Wells Fargo & Company MN lifted its stake in Corbus Pharmaceuticals Holdings by 1,859.0% in the 3rd quarter. Wells Fargo & Company MN now owns 52,893 shares of the biopharmaceutical company’s stock valued at $379,000 after purchasing an additional 50,193 shares during the last quarter. Cambridge Investment Research Advisors Inc. bought a new position in Corbus Pharmaceuticals Holdings in the 3rd quarter valued at approximately $190,000. Bank of New York Mellon Corp lifted its stake in Corbus Pharmaceuticals Holdings by 9.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 150,135 shares of the biopharmaceutical company’s stock valued at $1,073,000 after purchasing an additional 13,323 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System bought a new position in Corbus Pharmaceuticals Holdings in the 3rd quarter valued at approximately $108,000. 29.20% of the stock is owned by institutional investors and hedge funds.

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Insider Buying and Selling by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.